explore -WSS

explore

author：knowledge 2025-09-29 01:36:24 - browse：7736

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Gut bacteria may contribute to kidney autoimmunity, study finds

leisure time

WSS

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Harvard scientists, with Google, unveil the most detailed brain map ever

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

U.K. decision on ALS drug has neurologists, advocates up in arms

Researchers test human milk's ability to repair gut microbiome

Lack of darker skin in textbooks, journals harms patients of color

hotspot

explore

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Dobbs anniversary: the lost opportunity of abortion as health care

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Wildfire smoke exposes gaps in outdoor worker protections

Young boy dies in trial for Pfizer Duchenne gene therapy

Duchenne breakthrough therapy leaves behind pioneering families

Mass General Brigham physicians react to latest merger step

Hollywood unions extend contract negotiations for actors

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

explore

Multiple sclerosis has subtypes with different best treatments: study

US soldier in North Korean custody after crossing DMZ line

A strong 6.5

A Theranos scientist

Pancreatic cancer is often deadly, but new discoveries are raising hope

Why you get paid to donate plasma but not blood

Wikipedia

leisure time

explore

entertainment